Myers et al., 2005 - Google Patents
Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancerMyers et al., 2005
View PDF- Document ID
- 10556587688228137750
- Author
- Myers R
- Greiner S
- Harvey M
- Soeffker D
- Frenzke M
- Abraham K
- Shaw A
- Rozenblatt S
- Federspiel M
- Russell S
- Peng K
- Publication year
- Publication venue
- Cancer gene therapy
External Links
Snippet
Oncolytic viruses are promising cytoreductive agents for cancer treatment but extensive human testing will be required before they are made commercially available. Here, we investigated the oncolytic potential of two commercially available live attenuated vaccines …
- 230000000174 oncolytic 0 title abstract description 27
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
- C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
- C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses
- C12N2750/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses ssDNA Viruses
- C12N2750/14011—Parvoviridae
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Myers et al. | Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer | |
| Msaouel et al. | Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview | |
| Msaouel et al. | Engineered measles virus as a novel oncolytic therapy against prostate cancer | |
| Parato et al. | Recent progress in the battle between oncolytic viruses and tumours | |
| Kaufman et al. | Oncolytic viruses: a new class of immunotherapy drugs | |
| Iankov et al. | Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy | |
| Miest et al. | Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis | |
| TWI653334B (en) | Composition characterized by attenuated Xincheng chicken plague virus and method for treating tumor formation | |
| Iankov et al. | Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model | |
| Lech et al. | Use of attenuated paramyxoviruses for cancer therapy | |
| Liu et al. | Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus | |
| Estevez-Ordonez et al. | Immunovirotherapy for the treatment of glioblastoma and other malignant gliomas | |
| Fielding | Measles as a potential oncolytic virus | |
| Atsumi et al. | Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus | |
| Blechacz et al. | Measles virus as an oncolytic vector platform | |
| WO2019015601A1 (en) | Virus for treating tumors | |
| Wei et al. | Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas | |
| Volovat et al. | Oncolytic virotherapy: a new paradigm in cancer immunotherapy | |
| Bian et al. | Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein | |
| Tkacheva et al. | Targeted therapy of human glioblastoma combining the oncolytic properties of parvovirus H-1 and attenuated strains of the vaccinia virus | |
| JP7373168B2 (en) | Echovirus to treat tumors | |
| JP5793242B2 (en) | Oncolytic viral therapy to treat sarcoma | |
| JP5897700B2 (en) | Avian metapneumovirus in oncolysis | |
| US20210154249A1 (en) | Coxsackie virus b for treating tumors | |
| DK2629783T3 (en) | Changing the targeting of rat parvovirus H-1PV against cancer cells by genetic engineering of the capsid |